Elsevier

Clinics in Chest Medicine

Volume 33, Issue 3, September 2012, Pages 559-570
Clinics in Chest Medicine

Resolution of Inflammation in Asthma

https://doi.org/10.1016/j.ccm.2012.06.006Get rights and content

Introduction

Asthma is characterized by increased and chronic airway inflammation.1 Airway sampling by bronchoscopy or sputum analysis most often reveals abundant eosinophils and activated T cells, and lung histology demonstrates airway remodeling with disordered mucosal epithelium.2, 3 Whereas noxious stimuli, including potential allergens, can initiate an acute inflammatory response that is self-limited, nonresolving inflammation is linked to asthma and other chronic inflammatory diseases (reviewed in Ref.4). The overall magnitude and duration of inflammation depends on competing physiologic processes, namely prophlogistic mechanisms that amplify inflammation and endogenous braking programs that control the resolution of inflammation (reviewed in Ref.5). In health, the resolution of inflammation is an active coordinated process that is spatiotemporally controlled by endogenously generated autacoids at sites of inflammation.6 While several classes of mediators participate in resolution, the enzymatic transformations of polyunsaturated fatty acids (PUFAs) to specific proresolving agonists are of particular interest. The discovery that PUFAs are essential dietary constituents7 led to the recognition of their immunoregulatory actions.8 These PUFA-derived mediators display cell type–selective anti-inflammatory, proresolving, antifibrotic, antiangiogenic, and anti-infective actions (reviewed in Ref.5).

This article reviews recent findings on new mechanisms and mediators for resolution of airway inflammation, with a focus on their relevance to asthma.

Section snippets

Resolution of acute inflammation

The acute inflammatory response to inhaled pathogens, particles, and toxins is inherently protective and essential to ultimately restoring the injured airway to its normal physiologic functioning. Acute inflammation is initiated within minutes of recognition of a danger signal, and is generally self-limited, resolving within hours or days. In several conditions that are clinically recognized as lung disease, including asthma, chronic inflammation persists. Somehow, a naturally protective

Polyunsaturated fatty acid metabolism to proresolving mediators

PUFAs are essential nutrients. The ω-6 PUFA, arachidonic acid (AA; 20:4n-6) is incorporated into cellular phospholipids, and on cell activation, specific phospholipase A2 enzymes release AA from the sn-2 fatty acyl bond of phospholipids. AA can then be converted enzymatically by COX to prostaglandins (PGs), by ALOX5 to leukotrienes (LTs) or, by ALOX5 in collaboration with ALOX12 or ALOX15 to lipoxins (LXs).5, 38 The ω-3 PUFAs eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA;

Novel ω-3 fatty acid–derived lipid mediators

Population surveys report that diets rich in ω-3 fatty acids are associated with lower asthma prevalence.89 However, the underlying mechanisms behind this observation remain unclear. Recently, specialized proresolving mediators derived from ω-3 fatty acids were identified in self-limited models of acute inflammation, and were termed resolvins (resolution-phase interaction products).9, 10 Similar to LXs, resolvins can be generated via ALOX5-catalyzed reactions during transcellular biosynthesis

Summary

The resolution of inflammation is an integral and natural part of the physiologic response to tissue injury, infection, and allergen or other noxious stimuli. Resolution is an active process with highly regulated cellular and biochemical events. Several discrete families of natural small molecules have recently been uncovered using a lipidomics approach. Select members are proresolving and stimulate tissue catabasis. These agents include resolvins, protectins and, most recently, maresins.

First page preview

First page preview
Click to open first page preview

References (120)

  • K. Gronert et al.

    Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses

    Am J Pathol

    (2001)
  • I. Vachier et al.

    Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound

    J Allergy Clin Immunol

    (2005)
  • S. Bilal et al.

    Fat-1 transgenic mice with elevated omega-3 fatty acids are protected from allergic airway responses

    Biochim Biophys Acta

    (2011)
  • H. Aoki et al.

    Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma

    Biochem Biophys Res Commun

    (2008)
  • C.H. Fanta

    Asthma

    N Engl J Med

    (2009)
  • J. Bousquet et al.

    Asthma. From bronchoconstriction to airways inflammation and remodeling

    Am J Respir Crit Care Med

    (2000)
  • W.W. Busse et al.

    Asthma

    N Engl J Med

    (2001)
  • C.N. Serhan

    Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways

    Annu Rev Immunol

    (2007)
  • B.D. Levy et al.

    Lipid mediator class switching during acute inflammation: signals in resolution

    Nat Immunol

    (2001)
  • C.N. Serhan

    The resolution of inflammation: the devil in the flask and in the details

    FASEB J

    (2011)
  • C.N. Serhan et al.

    Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing

    J Exp Med

    (2000)
  • C.N. Serhan et al.

    Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals

    J Exp Med

    (2002)
  • J. Savill et al.

    Phagocytic docking without shocking

    Nature

    (1998)
  • J.S. Savill et al.

    Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages

    J Clin Invest

    (1989)
  • V.A. Fadok et al.

    Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF

    J Clin Invest

    (1998)
  • J. Savill et al.

    Corpse clearance defines the meaning of cell death

    Nature

    (2000)
  • D.W. Gilroy et al.

    Inflammatory resolution: new opportunities for drug discovery

    Nat Rev Drug Discov

    (2004)
  • G.L. Bannenberg et al.

    Molecular circuits of resolution: formation and actions of resolvins and protectins

    J Immunol

    (2005)
  • C.N. Serhan et al.

    Resolution of inflammation: the beginning programs the end

    Nat Immunol

    (2005)
  • G. Majno

    Cells, tissues and disease: principles of general pathology

    (1996)
  • P.G. Woodruff et al.

    Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids

    Proc Natl Acad Sci U S A

    (2007)
  • P.G. Woodruff et al.

    T-helper type 2-driven inflammation defines major subphenotypes of asthma

    Am J Respir Crit Care Med

    (2009)
  • B. Samuelsson

    From studies of biochemical mechanisms to novel biological mediators: prostaglandin endoperoxides, thromboxanes and leukotrienes

  • M. Wills-Karp et al.

    Interleukin-13: central mediator of allergic asthma

    Science

    (1998)
  • G. Zhen et al.

    IL-13 and epidermal growth factor receptor have critical but distinct roles in epithelial cell mucin production

    Am J Respir Cell Mol Biol

    (2007)
  • C.N. Serhan et al.

    Resolution of inflammation: state of the art, definitions and terms

    FASEB J

    (2007)
  • C. Bandeira-Melo et al.

    Cyclooxygenase-2-derived prostaglandin E2 and lipoxin A4 accelerate resolution of allergic edema in Angiostrongylus costaricensis-infected rats: relationship with concurrent eosinophilia

    J Immunol

    (2000)
  • J.F. Maddox et al.

    Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction

    J Exp Med

    (1996)
  • C. Godson et al.

    Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages

    J Immunol

    (2000)
  • A. Ariel et al.

    Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression

    Nat Immunol

    (2006)
  • D.W. Lawrence et al.

    Antiadhesive role of apical decay-accelerating factor (CD55) in human neutrophil transmigration across mucosal epithelia

    J Exp Med

    (2003)
  • E.L. Campbell et al.

    Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution

    FASEB J

    (2007)
  • G. Canny et al.

    Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia

    Proc Natl Acad Sci U S A

    (2002)
  • D.G. Souza et al.

    The required role of endogenously produced lipoxin A4 and annexin-1 for the production of IL-10 and inflammatory hyporesponsiveness in mice

    J Immunol

    (2007)
  • K. Fukunaga et al.

    Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury

    J Immunol

    (2005)
  • D.W. Gilroy et al.

    Inducible cyclooxygenase may have anti-inflammatory properties

    Nat Med

    (1999)
  • J.M. Schwab et al.

    Resolvin E1 and protectin D1 activate inflammation-resolution programmes

    Nature

    (2007)
  • B. Samuelsson et al.

    Leukotrienes and lipoxins: structures, biosynthesis, and biological effects

    Science

    (1987)
  • S.D. Freedman et al.

    Association of cystic fibrosis with abnormalities in fatty acid metabolism

    N Engl J Med

    (2004)
  • C.M. Albert et al.

    Blood levels of long-chain n-3 fatty acids and the risk of sudden death

    N Engl J Med

    (2002)
  • Cited by (48)

    • Inflammation resolution in environmental pulmonary health and morbidity

      2022, Toxicology and Applied Pharmacology
      Citation Excerpt :

      In asthmatics, apoptotic cell accumulation promotes chronic airway inflammation, excess mucus production, and scarring (Yang et al., 2021; Martinez and Cook, 2021). Reduced LX levels observed in asthmatic lungs could be due to SPM deficiencies in asthma (Yang et al., 2021), either from defective biosynthesis or dysregulated expression of the LXA4 receptor ALX/FPR2 (Levy et al., 2005; Levy et al., 2012; Kazani et al., 2013). Enhanced LT production and reduced LX synthesis is implicated in severe asthma exacerbation (Levy, 2005) and may also result from PUFA deficiency (AA, DHA) in the airway mucosa (Duvall and Levy, 2016).

    • Altered tissue specialized pro-resolving mediators in chronic rhinosinusitis

      2021, Prostaglandins Leukotrienes and Essential Fatty Acids
      Citation Excerpt :

      These endogenously produced autacoids consist of arachidonic acid (AA) derived lipoxins (LXA4, LXB4), eicosapentanoic acid (EPA) derived resolvins (RvE1, RvE2), and docosahexaenoic acid (DHA) derived protectins (PD1), resolvins (RvD1, RvD2, RvD3), and maresins (MaR1, MaR2). Each of these compounds has spatiotemporally controlled and tissue-specific actions, which include halting neutrophil chemotaxis, increasing clearance of apoptotic neutrophils from the inflammatory milieu (efferocytosis), and directing the local chemokine and cytokine environment towards homeostasis [8] Dysregulation of these pathways contributes to the pathogenesis of several chronic disease states such as bronchial asthma [9]. Although earlier studies reported lipoxin deficiency in CRS-AERD [10], a detailed examination of eicosanoid and docosanoid derivatives, particularly SPMs, is lacking in CRS.

    • Granulocyte-targeted therapies for airway diseases

      2020, Pharmacological Research
      Citation Excerpt :

      Tralokinumab, another anti-IL-13 mAb, also showed inconsistent effects on asthma exacerbation rate in patients with severe, uncontrolled asthma [116] and, similarly to lebrikizumab, was recently been reported to benefit patients with moderate-to-severe atopic dermatitis in a phase III clinical trial [117]. The sustained granulocytic inflammation in asthma suggests that part of asthma pathobiology may be related to an impairment of resolution of inflammation [118]. Resolution of inflammation is an active process coordinated by specialized pro-resolving mediators (SPMs) that leads to termination of inflammation [119].

    • “Redox lipidomics technology: Looking for a needle in a haystack”

      2019, Chemistry and Physics of Lipids
      Citation Excerpt :

      Various types of mass-spectrometry (MS) have become, by far, the most sensitive, accurate and quantitative methodology for studies of lipid peroxidation products. Both matrix assisted laser desorption ionization (MALDI) and electrospray ionization (ESI) have been widely used for the analysis of PLs and their oxidized products (Lewis et al., 1990; Levy et al., 2012). Recent technological improvements in mass spectrometric platforms allow for enhanced sensitivity, resolution and scan speed of mass ions.

    View all citing articles on Scopus

    Funding sources: Dr Levy: National Institutes of Health. Dr Vachier: Med Bio Med. Dr Serhan: National Institutes of Health.

    This research was supported in part by the US National Institutes of Health grants AI068084, P01-GM095467, U10-HL109172 and P50-HL107166.

    Conflicts of interest: Dr Levy: Consultant for Resolvyx Pharmaceuticals; patents licensed to Bayer Healthcare and Resolvyx; Equity in Resolvyx Pharmaceuticals. Dr Levy's interests were reviewed and are managed by the Brigham and Women's Hospital and Partners HealthCare in accordance with their conflict of interest policies. Dr Vachier: No conflict of Interest. Dr Serhan is an inventor of patents (resolvins) and proresolving mediators and related compounds assigned to Brigham and Women's Hospital and licensed to Resolvyx Pharmaceuticals. Dr Serhan is a scientific founder of Resolvyx Pharmaceuticals and owns equity in the company. His interests were reviewed and are managed by the Brigham and Women's Hospital and Partners HealthCare in accordance with their conflict of interest policies.

    View full text